<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have reported previously that posttreatment with NG-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>), an inhibitor of the nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase, reduced the volume of cortical and striatal <z:mpath ids='MPATH_124'>infarct</z:mpath> induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we investigated the mechanisms by which L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (3 mg/kg i.p.) is neuroprotective in this model of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>First, we have shown the reversal of the neuroprotective effect of L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> by a coinjection of <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Second, in order to determine by which mechanism nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> exacerbates neuronal damage produced by focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, we studied the effect of the inhibition of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase by L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> on the histological consequences of a focal injection of <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) in the striatum, and on the striatal overflow of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> and <z:chebi fb="0" ids="29995">aspartate</z:chebi> induced either by K+ depolarization or by focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We have found that L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> treatment reduced the excitotoxic damage produced by <z:chebi fb="0" ids="31882">NMDA</z:chebi> injection </plain></SENT>
<SENT sid="5" pm="."><plain>By using microdialysis, we have shown that the <z:chebi fb="0" ids="29103">K(+)</z:chebi>- and the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> efflux was reduced by 52 and 30%, respectively, after the L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> treatment </plain></SENT>
<SENT sid="6" pm="."><plain>These results indicate that nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthesis induced by the <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor overstimulation is one of the major events leading to neuronal damage </plain></SENT>
<SENT sid="7" pm="."><plain>One possible mechanism by which nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> may contribute to the excitotoxic process is by facilitating the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> overflow </plain></SENT>
</text></document>